<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159103</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-3927-P101</org_study_id>
    <nct_id>NCT04159103</nct_id>
  </id_info>
  <brief_title>Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia</brief_title>
  <official_title>A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3927 in participants 1 year of&#xD;
      age and older with propionic acidemia (PA). The study is designed to characterize baseline&#xD;
      biomarker levels followed by assessment of safety, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of different doses of mRNA-3927 in participants affected by PA as part&#xD;
      of the Dose Optimization phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the Dose Optimization Stage, after each dose cohort is fully enrolled, and 21 days&#xD;
      after the final participant in the cohort receives their first dose of study drug, the&#xD;
      Sponsor will review the totality of available safety data in conjunction with all available&#xD;
      PK/PD data. Based on this review, the Sponsor will recommend a revised dose and/or dosing&#xD;
      interval. The Sponsor will abide by predefined constraints as to the maximum percentage&#xD;
      change in dose and dose interval. A maximum of 5 cohorts will be enrolled into the study.&#xD;
&#xD;
      Upon establishment of a dose with acceptable safety and pharmacodynamic activity, additional&#xD;
      participants will be enrolled in a Dose Expansion Stage to allow for further characterization&#xD;
      of the safety and pharmacodynamics of mRNA-3927.&#xD;
&#xD;
      Participants in both phases of study will participate in a predosing observational period,&#xD;
      followed by a treatment period, and then a followup period after withdrawal of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">January 6, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with an Adverse Event (AE)</measure>
    <time_frame>Day 1 (initial mRNA-3927 dose) up to Week 149 (End of Study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) after Administration of mRNA-3927</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>Baseline (predose levels) to postdose levels measured after single and after repeated administrations of mRNA-3927</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>Baseline (predose levels) to postdose levels measured after single and after repeated administrations of mRNA-3927</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC)</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>Baseline (predose levels) to postdose levels measured after single and after repeated administrations of mRNA-3927</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Anti-Polyethylene Glycol Antibodies</measure>
    <time_frame>Baseline through Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma 2-Methylcitrate (2-MC) Levels at Week 36</measure>
    <time_frame>Baseline (Week -3), Week 36</time_frame>
    <description>Baseline (predose levels) to postdose levels measured after single and after repeated administrations of mRNA-3927.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma 3-Hydroxypropionic Acid (3-HP) Levels at Week 36</measure>
    <time_frame>Baseline (Week -3), Week 36</time_frame>
    <description>Baseline (predose levels) to postdose levels measured after single and after repeated administrations of mRNA-3927.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Propionic Acidemia</condition>
  <arm_group>
    <arm_group_label>Dose Optimization Stage: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 1 of mRNA-3927 by intravenous (IV) infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization Stage: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 2 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization Stage: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 3 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization Stage: Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 4 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization Stage: Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 5 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive the optimal dose of mRNA-3927 identified during the Dose Optimization Stage at 1 dose on Day 1 of each 21-day period for up to 10 doses during the approximate 30-week Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-3927</intervention_name>
    <description>mRNA-3927 dispersion for IV infusion</description>
    <arm_group_label>Dose Expansion Stage</arm_group_label>
    <arm_group_label>Dose Optimization Stage: Dose Level 1</arm_group_label>
    <arm_group_label>Dose Optimization Stage: Dose Level 2</arm_group_label>
    <arm_group_label>Dose Optimization Stage: Dose Level 3</arm_group_label>
    <arm_group_label>Dose Optimization Stage: Dose Level 4</arm_group_label>
    <arm_group_label>Dose Optimization Stage: Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be ≥1 year of age at the time of consent/assent (Inclusion of the&#xD;
             first 2 participants entering the study at the Dose Escalation stage will be&#xD;
             restricted to individuals age ≥8 years)&#xD;
&#xD;
          -  Confirmed diagnosis of propionic acidemia based on diagnosis by molecular genetic&#xD;
             testing (propionyl-CoA carboxylase subunit α [PCCA] and/or propionyl CoA carboxylase&#xD;
             subunit β [PCCB] mutations)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;30 milliliter (mL)/minute/1.73 m^2 as estimated&#xD;
             by Schwartz formula; or participants who receive chronic dialysis&#xD;
&#xD;
          -  History of organ transplantation or planned organ transplantation during the period of&#xD;
             study participation&#xD;
&#xD;
          -  QTc &gt;480 ms using Bazett's correction&#xD;
&#xD;
          -  Grade 3 or 4 heart failure according to the Modified Ross Heart Failure Classification&#xD;
             for Children or the New York Heart Association&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai - Clinical Research Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-3927</keyword>
  <keyword>Propionic Aciduria</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Inborn Amino Acid Metabolism, Inborn Errors</keyword>
  <keyword>Acidosis</keyword>
  <keyword>Acid-Base Imbalance</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Organic Acidemias</keyword>
  <keyword>Moderna</keyword>
  <keyword>mRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propionic Acidemia</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

